Mentor Pharmaceutical Consulting is
directed by Dr Gregory Russell-Jones, and specializes in providing advice to Government,
University and Pharmaceutical
groups in the areas of oral protein delivery, nanoparticle formulation, transdermal protein delivery, dissolution of Class II drugs, nanotheranostics, and cancer targeting.
Advice is given on choice of targeting
agents, chemistry of conjugation, optimization of conjugation,
nanoparticle formulation, targeting, scale up, in vitro and in vivo
Oral delivery systems have been developed for proteins
insulin, IGF, GHRP, Epo, Interferon, EGF, monoclonal antibodies, Fc
fusions, and antigens.
Transdermal delivery systems have been
developed for peptides and proteins including LHRH analogues, EGF, IGF,
Growth Hormone, insulin, monoclonal antibodies, Fc fusions, vitamin B12
Novel targeted delivery systems have been
developed for increased cancer targeting of imaging agents and cytotoxins to various tumour cells with greatly
increased specificity and efficacy. Various potential serum markers for
cancer diagnosis have been identified.
Mentor also identifies novel technology for protein delivery that is
available for licensing or co-development.
Advice is given either by email, phone contact or
face-to-face meetings. We are very patient and do our best to communicate
in an easy-to-understand fashion. We can also provide Powerpoint
presentations of your or our technology.
We like to collaborate and a friendly and co-operative
environment, however we do like to be paid for our advice, particularly if
it involves novel Intellectual Property.
Mentor has recently introduced a "Name and Shame" policy.
This policy has been necessary due to some of our more recent associations
where collaborators/associates have either not paid us or have used
information, ideas, concepts or data, provided to them under a
Confidentiality Agreement, to gain commercial advantage without payment to
Mentor. We believe that such behavior is unethical and we would like to
It has recently come to our attention that a company in
India with which we had an agreement has taken Intellectual Property made
available to them under the agreement and has sought to gain Commercial
Advantage of the property without compensation to Mentor. The property
concerned the use of the neonatal Fc receptor for oral delivery of
antibodies, the use of the intestinal insulin receptor for oral delivery
of insulin, the use of a biotin binding protein for detection and
treatment of cancer, and the use of the biotin uptake system for oral
delivery in general. If you become privy to such information please be
aware that the material, data, IP, presentations, publicity documents and
project plans are the property of Mentor.